Physician profile
Anisha E Mathi
NPI 1548627912
$5,253.55
in general payments reported to CMS, 2019-2025
19 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $376 · 2023: $1,553 · 2024: $1,131 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426 · Consulting Fee: $1,125 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.63 |
| Consulting Fee | $1,125.00 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,517.75 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $849.57 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $553.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $495.37 | 2023-2024 | Sotyktu |
| Abbvie INC. | $413.18 | 2022-2025 | |
| Mimedx Group, INC. | $303.99 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $249.19 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $247.05 | 2022-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $204.32 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $70.33 | 2023-2024 | Adbry |
| Mayne Pharma Commercial LLC | $65.08 | 2023 | |
| Arcutis Biotherapeutics, INC. | $64.65 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.56 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.56 | 2025 | Jublia, Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $37.30 | 2025 | Nemluvio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $29.71 | 2023 | Seysara |
| Ucb, INC. | $21.67 | 2024 | Bimzelx |
| Smith+Nephew, INC. | $21.14 | 2023 | Collagenase Santyl |
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Mathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.